Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million ...

Century Therapeutics (IPSC) has entered into an agreement for an investigator-initiated Phase 1/2 trial by Professors Georg Schett and Andreas ...

Chronic inflammation is linked to various health issues, and an anti-inflammatory diet can help manage weight and improve overall health. Celebrities like Vidya Balan and Samantha Ruth Prabhu have ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized ...

Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company is ...

Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM ...

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically ...